Three new products aimed at meeting the changing demands of global pharma-companies are being introduced by the pharmaceutical packaging equipment specialist, Sepha Ltd. They will be formally launched at Interpack, Dusseldorf on 8-14th May 2014.
Three new products aimed at meeting the changing demands of global pharma-companies are being introduced by the pharmaceutical packaging equipment specialist, Sepha Ltd.
The first machine, BottleScan, is the world’s first tool-less, non-destructive leak detection instrument for testing multiple induction-sealed bottles simultaneously. It incorporates force decay technology to test induction-sealed bottles for holes and weak seals without destroying the contents. Ahead of itsEuropean debut, BottleScan has already attracted orders from Asian and North American customers.
Press Out Universal Mini is a low volume, rapid product change over deblistering unit that enables product to be recovered from all blister pack types, particularlychild resistant,peel-able and senior-friendly packs. The unit has been developed to reflect changes in the pharmaceutical manufacturing market, where manufacturers are focusing on shorter runs of more bespoke, high value drugs in child resistant or senior-friendly blister packs.
Finally, EZ MedPakextends Sepha's 'EZ' range of low volume, package development unitsinto the wider medical packaging market. It is aimed specifically at medical device and packaging development teams who want to take control of their own pack designs and develop bespoke packs for small devices and pre-filled syringes.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.